ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

Learn more about whether Intra-Cellular Therapies, Inc. or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from ...

AstraZeneca and the Memorial Sloan Kettering Cancer Center (MSK) have tapped digital health tech company IgniteData to ...

Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 ...

Learn more about whether Corcept Therapeutics Incorporated or Intra-Cellular Therapies, Inc. is a better investment based on ...

Patients with rosacea experienced improvement with Emrosi, an oral minocycline hydrochloride extended-release product, ...

With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...

Adding nivolumab to neoadjuvant chemotherapy significantly improves response rates in high-risk early-stage ER+/HER2− breast ...

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.